Category Press Releases

Roche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

Roche Showcases Breakthrough Sequencing by Expansion (SBX) Technology and Sets New GUINNESS WORLD RECORD™ at ASHG 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled a series of groundbreaking advancements in its Sequencing by Expansion (SBX) technology during the American Society…

Read MoreRoche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma

Taiho Pharmaceutical Grants Exclusive Rights for PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement granting Taiho the rights to develop, manufacture,…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma

Zoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

Zoetis Receives Health Canada Approval for Lenivia® to Relieve Osteoarthritis Pain in Dogs Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia, a novel monoclonal…

Read MoreZoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

GSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older

GSK’s Shingrix Receives Approval in China to Protect Immunocompromised Adults Against Shingles GSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has granted approval for Shingrix—GSK’s Recombinant Zoster Vaccine (RZV)—for the prevention of shingles (herpes…

Read MoreGSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older

DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss

Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…

Read MoreDB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss

Oticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS

Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…

Read MoreOticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS

IDT and Hamilton Partner to Automate NGS and Boost Biomarker Discovery

IDT and Hamilton Partner to Automate NGS Workflows, Accelerating Biomarker and Genomic Discovery Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a new strategic partnership with precision laboratory automation pioneer Hamilton (Hamilton Company and Hamilton Bonaduz…

Read MoreIDT and Hamilton Partner to Automate NGS and Boost Biomarker Discovery
Pulse Biosciences

Pulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025

Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of its novel nPulse™ technology based on Nanosecond Pulsed Field Ablation™…

Read MorePulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025